VEGFA and neoplasm: This immune-enriched but exhausted tumor immune microenvironment is associated with significantly longer PFS in patients treated with combined immunotherapy using anti-PD-L1 and anti-VEGF antibodies, as confirmed by chemical-shift MR imaging [89].